Advanced search
1 file | 2.02 MB

Modelling and sensitivity analysis of urinary platinum excretion in anticancer chemotherapy for the recovery of platinum

Karel Folens (UGent) , Séverine Mortier (UGent) , Janis Baeten (UGent) , Karen Couvreur (UGent) , Robin Michelet (UGent) , Krist V Gernaey, Thomas De Beer (UGent) , Gijs Du Laing (UGent) and Ingmar Nopens (UGent)
Author
Organization
Abstract
Platinum (Pt) based antineoplastics are important in cancer therapy. To date the Pt which is urinary excreted by the patients ends up in wastewater. This is disadvantageous from both an economic as from an ecological point of view because Pt is a valuable material and the excretion products are toxic for aquatic organisms. Therefore, efforts should be made to recover the Pt. The urinary excretion of Pt from two antineoplastics are taken under consideration, i.e. cisplatin and carboplatin. Using these reference compounds, a scenario analysis based on administration statistics from Ghent University Hospital in combination with compartmental models for urinary Pt excretion was performed to simulate the average Pt excretion profile during common treatment schemes. These average profiles can be used to assess the technical, social and economic feasibility of Ptrecovery from urine or wastewater. A one-compartment model is used for cisplatin, which is calibrated using the experimental data of six patients. In contrast, a two-compartment model with parameters from literature is used for carboplatin. A Global Sensitivity Analysis revealed kel, the rate constant of elimination, is the most sensitive parameter in the one-compartment model whereas Qu, the urine production rate, was the most sensitive in the two-compartment model for the Pt concentration Cu in urine and the excreted mass of Pt via urine. A GLUE uncertainty analysis showed that all experimental data are within the 95% uncertainty boundaries.
Keywords
Platinum excretion, precious metal recovery, sustainable materials management, cancerostatic platinum compounds, modelling, sensitivity analysis, HOSPITAL EFFLUENTS, PHARMACOKINETICS, CISPLATIN, CARBOPLATIN, CANCER, INFUSION, DESIGN

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 2.02 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Folens, Karel, Séverine Mortier, Janis Baeten, Karen Couvreur, Robin Michelet, Krist V Gernaey, Thomas De Beer, Gijs Du Laing, and Ingmar Nopens. 2016. “Modelling and Sensitivity Analysis of Urinary Platinum Excretion in Anticancer Chemotherapy for the Recovery of Platinum.” Ed. Klaus Kümmerer. Sustainable Chemistry and Pharmacy 4: 46–56.
APA
Folens, K., Mortier, S., Baeten, J., Couvreur, K., Michelet, R., Gernaey, K. V., De Beer, T., et al. (2016). Modelling and sensitivity analysis of urinary platinum excretion in anticancer chemotherapy for the recovery of platinum. (K. Kümmerer, Ed.)SUSTAINABLE CHEMISTRY AND PHARMACY, 4, 46–56.
Vancouver
1.
Folens K, Mortier S, Baeten J, Couvreur K, Michelet R, Gernaey KV, et al. Modelling and sensitivity analysis of urinary platinum excretion in anticancer chemotherapy for the recovery of platinum. Kümmerer K, editor. SUSTAINABLE CHEMISTRY AND PHARMACY. 2016;4:46–56.
MLA
Folens, Karel, Séverine Mortier, Janis Baeten, et al. “Modelling and Sensitivity Analysis of Urinary Platinum Excretion in Anticancer Chemotherapy for the Recovery of Platinum.” Ed. Klaus Kümmerer. SUSTAINABLE CHEMISTRY AND PHARMACY 4 (2016): 46–56. Print.
@article{8506698,
  abstract     = {Platinum (Pt) based antineoplastics are important in cancer therapy. To date the Pt which is urinary excreted by the patients ends up in wastewater. This is disadvantageous from both an economic as from an ecological point of view because Pt is a valuable material and the excretion products are toxic for aquatic organisms. Therefore, efforts should be made to recover the Pt. The urinary excretion of Pt from two antineoplastics are taken under consideration, i.e. cisplatin and carboplatin. Using these reference compounds, a scenario analysis based on administration statistics from Ghent University Hospital in combination with compartmental models for urinary Pt excretion was performed to simulate the average Pt excretion profile during common treatment schemes. These average profiles can be used to assess the technical, social and economic feasibility of Ptrecovery from urine or wastewater. A one-compartment model is used for cisplatin, which is calibrated using the experimental data of six patients. In contrast, a two-compartment model with parameters from literature is used for carboplatin. A Global Sensitivity Analysis revealed kel, the rate constant of elimination, is the most sensitive parameter in the one-compartment model whereas Qu, the urine production rate, was the most sensitive in the two-compartment model for the Pt concentration Cu in urine and the excreted mass of Pt via urine. A GLUE uncertainty analysis showed that all experimental data are within the 95\% uncertainty boundaries.},
  author       = {Folens, Karel and Mortier, S{\'e}verine and Baeten, Janis and Couvreur, Karen and Michelet, Robin and Gernaey, Krist V and De Beer, Thomas and Du Laing, Gijs and Nopens, Ingmar},
  editor       = {K{\"u}mmerer, Klaus},
  issn         = {2352-5541},
  journal      = {SUSTAINABLE CHEMISTRY AND PHARMACY},
  keyword      = {Platinum excretion,precious metal recovery,sustainable materials management,cancerostatic platinum compounds,modelling,sensitivity analysis,HOSPITAL EFFLUENTS,PHARMACOKINETICS,CISPLATIN,CARBOPLATIN,CANCER,INFUSION,DESIGN},
  language     = {eng},
  pages        = {46--56},
  title        = {Modelling and sensitivity analysis of urinary platinum excretion in anticancer chemotherapy for the recovery of platinum},
  url          = {http://dx.doi.org/10.1016/j.scp.2016.10.001},
  volume       = {4},
  year         = {2016},
}

Altmetric
View in Altmetric